Hutchmed China Ltd ADR (HCM)

$12.64 +0.08 (0.64%)
Market Cap 2.19B
Revenue (ttm) 548.51M
Net Income (ttm) 456.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 53.04
Profit Margin 83.30%
Debt to Equity Ratio 0.07
Volume 284,800
Avg Vol 52,140
Day's Range N/A - N/A
Shares Out 174.47M
Stochastic %K 81%
Beta 0.23
Analysts Sell
Price Target $18.90

Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung c...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 852 2121 8200
Address:
Cheung Kong Center, 48th floor 2 Queen's Road Central, Hong Kong, Hong Kong
flychicken1991
flychicken1991 Aug. 17 at 2:50 PM
$HCM Positive (88%): shares face upward price pressure because successful late-stage trial results increase the perceived probability that savolitinib can progress toward broader regulatory and commercial use. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/908f4ef0a39835b6?utm_source=stocktwits&utm_medium=story_url
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 17 at 12:19 PM
$HCM (+6.6% pre) HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® https://ooc.bz/l/111337
0 · Reply
Polip
Polip Aug. 17 at 9:34 AM
$HCM severely mispriced $AZN $XBI
0 · Reply
anvesti
anvesti Aug. 12 at 7:42 PM
Anvesti opened a long position $HCM · Entry $12.27 Model: ml_model_v3 · Score: 75.5
0 · Reply
interestingtimes
interestingtimes Jul. 31 at 11:45 PM
$HCM https://www.investing.com/news/transcripts/earnings-call-transcript-hutchmed-posts-solid-h1-2026-growth-stock-edges-up-93CH-4824518
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-hutchison-china-meditech-limited-stock/ $HCM HUTCHMED Earnings Transcript
0 · Reply
anvesti
anvesti Jul. 29 at 7:56 PM
Anvesti closed a long position $HCM 🟢 +5.03% $10.84 → $11.38 Model: ml_model_v3 · Score: 75.5 Reason: Earnings Protection · 19 days
0 · Reply
LewisDaKat
LewisDaKat Jul. 2 at 8:30 PM
$HCM HUTCHMED Announces NMPA Approval for ORPATHYS for the treatment of Gastric Cancer Patients with MET Amplification https://marketwirenews.com/stock/hcm/news/hutchmed-announces-nmpa-approval-for-orpathys-xae-fo-7272928322823748.html?utm_source=stocktwits
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 2 at 12:50 PM
$HCM (+7.1% pre) HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification https://ooc.bz/l/106753
0 · Reply
anvesti
anvesti Jul. 1 at 7:53 PM
Anvesti opened a long position $HCM · Entry $10.84 Model: ml_model_v3 · Score: 75.5
0 · Reply
Latest News on HCM
HUTCHMED's ORPATHYS-TAGRISSO Combo Shows Significant PFS, OS Benefit In Phase III Trial

2026-08-17T06:59:34.000Z - 2 days ago

HUTCHMED's ORPATHYS-TAGRISSO Combo Shows Significant PFS, OS Benefit In Phase III Trial

Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso

2026-08-17T00:25:05.000Z - 2 days ago

Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso

HCM

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

Sun, 16 Aug 2026 20:00:00 -0400 - 2 days ago

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

HUTCHMED H1 Earnings Call Highlights

Thu, 30 Jul 2026 13:08:14 -0400 - 19 days ago

HUTCHMED H1 Earnings Call Highlights

HUTCHMED (China) Earnings Call Transcript: H1 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

HUTCHMED (China) Earnings Call Transcript: H1 2026

HUTCHMED (China) Quarterly report: H1 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

HUTCHMED (China) Quarterly report: H1 2026

HUTCHMED (China) Slides: H1 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

HUTCHMED (China) Slides: H1 2026

Hutchmed price target lowered to $14 from $16 at Goldman Sachs

2026-07-23T10:06:10.000Z - 27 days ago

Hutchmed price target lowered to $14 from $16 at Goldman Sachs

A Look at HUTCHMED (China) Ltd (HCM) After 4.4% Gain -- GF Value $13.93 vs Price $11.29

2026-07-21T00:28:49.000Z - 4 weeks ago

A Look at HUTCHMED (China) Ltd (HCM) After 4.4% Gain -- GF Value $13.93 vs Price $11.29

HUTCHMED (China) Ltd (HCM) Shares Fall 6.8% -- What GF Score of 79 Tells Investors

2026-07-18T00:55:10.000Z - 4 weeks ago

HUTCHMED (China) Ltd (HCM) Shares Fall 6.8% -- What GF Score of 79 Tells Investors

HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors

2026-07-16T01:07:51.000Z - 4 weeks ago

HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors

Hutchmed price target lowered to $17 from $20 at BofA

2026-07-07T13:20:12.000Z - 6 weeks ago

Hutchmed price target lowered to $17 from $20 at BofA

Hutchmed announces China NMPA approval for Orpathys NDA

2026-07-02T09:05:10.000Z - 6 weeks ago

Hutchmed announces China NMPA approval for Orpathys NDA

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

Jul 2, 2026, 4:30 AM EDT - 6 weeks ago

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

HCM

HUTCHMED to Announce 2026 Half-Year Financial Results

Jun 30, 2026, 4:30 AM EDT - 7 weeks ago

HUTCHMED to Announce 2026 Half-Year Financial Results

HCM

Syndio Acquires Embrace.ai

Jun 23, 2026, 12:30 PM EDT - 2 months ago

Syndio Acquires Embrace.ai

HCM

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

Jun 16, 2026, 7:00 AM EDT - 2 months ago

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

EWTX HCM

isolved Honors Top-Performing Partners at Annual Connect for Partners Event

Jun 15, 2026, 8:30 PM EDT - 2 months ago

isolved Honors Top-Performing Partners at Annual Connect for Partners Event

HCM

isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees

Jun 15, 2026, 12:00 PM EDT - 2 months ago

isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees

HCM

Paychex Recognized as a Top WorkTech Company by TIME

Jun 15, 2026, 9:30 AM EDT - 2 months ago

Paychex Recognized as a Top WorkTech Company by TIME

HCM PAYX

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

Jun 11, 2026, 8:00 PM EDT - 2 months ago

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

HCM

Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley

2026-05-28T21:09:08.000Z - 2 months ago

Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

May 21, 2026, 8:00 PM EDT - 3 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

HCM

Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination

2026-05-21T10:10:55.000Z - 3 months ago

Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination

Hutchmed, Innovent Biologics announce China NMPA approval for NDA

2026-05-21T10:05:23.000Z - 3 months ago

Hutchmed, Innovent Biologics announce China NMPA approval for NDA

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

May 21, 2026, 6:00 AM EDT - 3 months ago

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HCM

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

May 21, 2026, 6:00 AM EDT - 3 months ago

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HCM

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites

May 20, 2026, 10:00 AM EDT - 3 months ago

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites

HCM

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms

May 18, 2026, 10:00 AM EDT - 3 months ago

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms

HCM

Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

May 13, 2026, 2:09 PM EDT - 3 months ago

Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

HCM

Hutchmed says NDA for sovleplenib accepted in China

2026-04-29T10:46:12.000Z - 4 months ago

Hutchmed says NDA for sovleplenib accepted in China

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference

Apr 28, 2026, 10:00 AM EDT - 4 months ago

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference

HUTCHMED (China) Slides: Deutsche Bank ADR Virtual Investor Conference

Apr 28, 2026, 10:00 AM EDT - 4 months ago

HUTCHMED (China) Slides: Deutsche Bank ADR Virtual Investor Conference

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

Apr 8, 2026, 8:00 PM EDT - 4 months ago

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

HCM

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

Mar 22, 2026, 8:00 PM EDT - 5 months ago

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HCM

Hutchmed price target lowered to $20 from $21 at BofA

2026-03-10T11:30:35.000Z - 5 months ago

Hutchmed price target lowered to $20 from $21 at BofA

Hutchmed discontinues all active tazemetostat clinical trials

2026-03-09T09:40:32.000Z - 5 months ago

Hutchmed discontinues all active tazemetostat clinical trials

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

Mar 9, 2026, 5:30 AM EDT - 5 months ago

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HCM

Hutchmed price target lowered to $21 from $22 at BofA

2026-03-06T13:16:28.000Z - 5 months ago

Hutchmed price target lowered to $21 from $22 at BofA

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

Mar 6, 2026, 3:30 AM EST - 5 months ago

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

HCM

HUTCHMED (China) Earnings Call Transcript: H2 2025

Mar 5, 2026, 7:30 PM EST - 5 months ago

HUTCHMED (China) Earnings Call Transcript: H2 2025

HUTCHMED (China) Annual report: H2 2025

Mar 5, 2026, 7:30 PM EST - 5 months ago

HUTCHMED (China) Annual report: H2 2025

HUTCHMED (China) Annual report: H2 2025

Mar 5, 2026, 7:30 PM EST - 5 months ago

HUTCHMED (China) Annual report: H2 2025

HUTCHMED (China) Slides: H2 2025

Mar 5, 2026, 7:30 PM EST - 5 months ago

HUTCHMED (China) Slides: H2 2025

HUTCHMED (China) Annual report: H2 2025

Mar 5, 2026, 7:30 PM EST - 5 months ago

HUTCHMED (China) Annual report: H2 2025

HUTCHMED to Announce 2025 Final Results

Feb 6, 2026, 3:30 AM EST - 6 months ago

HUTCHMED to Announce 2025 Final Results

HCM

Hutchmed reports publication of SACHI results in The Lancet

2026-01-14T10:35:22.000Z - 7 months ago

Hutchmed reports publication of SACHI results in The Lancet

AZN

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

Jan 13, 2026, 11:00 PM EST - 7 months ago

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

HCM

Hutchmed says Phase III of ESLIM-02 trial met primary endpoint

2026-01-07T00:05:12.000Z - 8 months ago

Hutchmed says Phase III of ESLIM-02 trial met primary endpoint

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Jan 6, 2026, 7:00 PM EST - 8 months ago

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HCM

Hutchmed price target lowered to $22 from $25 at BofA

2026-01-06T15:20:26.000Z - 8 months ago

Hutchmed price target lowered to $22 from $25 at BofA

Hutchmed initiates Phase III stage of Phase II/III trial

2026-01-05T00:35:06.000Z - 8 months ago

Hutchmed initiates Phase III stage of Phase II/III trial

Hutchmed initiates Phase III stage of Phase II/III trial

2026-01-05T00:30:07.000Z - 8 months ago

Hutchmed initiates Phase III stage of Phase II/III trial

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

Jan 4, 2026, 7:00 PM EST - 8 months ago

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

HCM

Hutchmed announces savolitinib new drug application acceptance in China

2025-12-30T10:10:10.000Z - 8 months ago

Hutchmed announces savolitinib new drug application acceptance in China

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

Dec 30, 2025, 5:00 AM EST - 8 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

HCM

Hutchmed announces fanregratinib NDA acceptance in China with priority review

2025-12-29T10:05:12.000Z - 8 months ago

Hutchmed announces fanregratinib NDA acceptance in China with priority review

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

Dec 29, 2025, 3:35 AM EST - 8 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

HCM

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

Dec 16, 2025, 7:00 PM EST - 8 months ago

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

HCM

Hutchmed announces contract renewal with the China NHSA

2025-12-08T01:50:06.000Z - 9 months ago

Hutchmed announces contract renewal with the China NHSA

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

Nov 26, 2025, 7:00 PM EST - 9 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

HUTCHMED (China) Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 10:30 AM EST - 9 months ago

HUTCHMED (China) Transcript: Jefferies London Healthcare Conference 2025

Hutchmed completes enrollment of SAFFRON Phase 3 trial of Orpathys+Tagrisso

2025-11-05T00:20:17.000Z - 10 months ago

Hutchmed completes enrollment of SAFFRON Phase 3 trial of Orpathys+Tagrisso

HCM

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference 2025

HUTCHMED (China) Slides: FY 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

HUTCHMED (China) Slides: FY 2025

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

Nov 2, 2025, 7:00 PM EST - 10 months ago

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

HUTCHMED (China) Transcript: Status Update

Oct 31, 2025, 8:00 AM EDT - 10 months ago

HUTCHMED (China) Transcript: Status Update

HUTCHMED (China) Slides: Status Update

Oct 31, 2025, 8:00 AM EDT - 10 months ago

HUTCHMED (China) Slides: Status Update

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Oct 14, 2025, 4:30 AM EDT - 11 months ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

Oct 13, 2025, 12:00 AM EDT - 11 months ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

Oct 1, 2025, 8:00 PM EDT - 11 months ago

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

Sep 11, 2025, 8:00 PM EDT - 1 year ago

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

Sep 4, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HUTCHMED Announces Appointment of Acting Chief Executive Officer

Aug 24, 2025, 8:20 PM EDT - 1 year ago

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

Aug 19, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED (China) Earnings Call Transcript: H1 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Earnings Call Transcript: H1 2025

HUTCHMED (China) Quarterly report: H1 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Quarterly report: H1 2025

HUTCHMED (China) Slides: H1 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Slides: H1 2025

HUTCHMED to Announce 2025 Half-Year Financial Results

Jul 3, 2025, 4:30 AM EDT - 1 year ago

HUTCHMED to Announce 2025 Half-Year Financial Results

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Jun 30, 2025, 4:30 AM EDT - 1 year ago

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED (China) Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 2:40 PM EDT - 1 year ago

HUTCHMED (China) Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

HUTCHMED (China) Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

HUTCHMED (China) Transcript: Jefferies Global Healthcare Conference 2025

HUTCHMED (China) Slides: Corporate Presentation

Jun 5, 2025, 2:00 AM EDT - 1 year ago

HUTCHMED (China) Slides: Corporate Presentation

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

Jun 4, 2025, 7:45 PM EDT - 1 year ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED (China) Transcript: Investor Update

Jun 2, 2025, 8:30 PM EDT - 1 year ago

HUTCHMED (China) Transcript: Investor Update

HUTCHMED (China) Press release: Investor Update

Jun 2, 2025, 8:30 PM EDT - 1 year ago

HUTCHMED (China) Press release: Investor Update

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

Jun 1, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

May 22, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference

May 15, 2025, 10:30 AM EDT - 1 year ago

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference

HUTCHMED (China) Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 2:20 PM EDT - 1 year ago

HUTCHMED (China) Transcript: Bank of America 2025 Healthcare Conference

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Apr 23, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

Apr 21, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Mar 21, 2025, 6:00 AM EDT - 1 year ago

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

Mar 20, 2025, 5:30 AM EDT - 1 year ago

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

US pharma restrictions won't affect Hutchmed operations, says CEO

Mar 20, 2025, 12:46 AM EDT - 1 year ago

US pharma restrictions won't affect Hutchmed operations, says CEO

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Mar 19, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED (China) Earnings Call Transcript: H2 2024

Mar 19, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Earnings Call Transcript: H2 2024

HUTCHMED (China) Annual report: H2 2024

Mar 19, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Annual report: H2 2024

HUTCHMED (China) Annual report: H2 2024

Mar 19, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Annual report: H2 2024

HUTCHMED (China) Annual report: H2 2024

Mar 19, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Annual report: H2 2024

HUTCHMED (China) Slides: H2 2024

Mar 19, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Slides: H2 2024

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

Mar 19, 2025, 7:00 AM EDT - 1 year ago

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Mar 18, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

Mar 6, 2025, 5:00 AM EST - 1 year ago

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED to Announce 2024 Final Results

Feb 19, 2025, 3:30 AM EST - 1 year ago

HUTCHMED to Announce 2024 Final Results

flychicken1991
flychicken1991 Aug. 17 at 2:50 PM
$HCM Positive (88%): shares face upward price pressure because successful late-stage trial results increase the perceived probability that savolitinib can progress toward broader regulatory and commercial use. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/908f4ef0a39835b6?utm_source=stocktwits&utm_medium=story_url
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 17 at 12:19 PM
$HCM (+6.6% pre) HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® https://ooc.bz/l/111337
0 · Reply
Polip
Polip Aug. 17 at 9:34 AM
$HCM severely mispriced $AZN $XBI
0 · Reply
anvesti
anvesti Aug. 12 at 7:42 PM
Anvesti opened a long position $HCM · Entry $12.27 Model: ml_model_v3 · Score: 75.5
0 · Reply
interestingtimes
interestingtimes Jul. 31 at 11:45 PM
$HCM https://www.investing.com/news/transcripts/earnings-call-transcript-hutchmed-posts-solid-h1-2026-growth-stock-edges-up-93CH-4824518
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-hutchison-china-meditech-limited-stock/ $HCM HUTCHMED Earnings Transcript
0 · Reply
anvesti
anvesti Jul. 29 at 7:56 PM
Anvesti closed a long position $HCM 🟢 +5.03% $10.84 → $11.38 Model: ml_model_v3 · Score: 75.5 Reason: Earnings Protection · 19 days
0 · Reply
LewisDaKat
LewisDaKat Jul. 2 at 8:30 PM
$HCM HUTCHMED Announces NMPA Approval for ORPATHYS for the treatment of Gastric Cancer Patients with MET Amplification https://marketwirenews.com/stock/hcm/news/hutchmed-announces-nmpa-approval-for-orpathys-xae-fo-7272928322823748.html?utm_source=stocktwits
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 2 at 12:50 PM
$HCM (+7.1% pre) HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification https://ooc.bz/l/106753
0 · Reply
anvesti
anvesti Jul. 1 at 7:53 PM
Anvesti opened a long position $HCM · Entry $10.84 Model: ml_model_v3 · Score: 75.5
0 · Reply
DrSilbergleit
DrSilbergleit Jun. 21 at 6:27 PM
$QS People see a scooter. Engineers see a miniature proving ground for next-generation energy systems. A multipack of six QSE-5 cells propels a scooter with astonishing force. Cc: $HCM $F $GM $TSLA Watch the video: https://x.com/silberschmelzer/status/1983582099123974240
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 12 at 12:20 PM
$HCM (+4.9% pre) HUTCHMED reports positive phase III data for sovleplenib in wAIHA https://ooc.bz/l/104982
0 · Reply
briefingcom
briefingcom May. 21 at 12:33 PM
$HCM: HUTCHMED and Innovent Biologics (IVBIY) jointly announce NMPA Approval for TYVYT in combination with ELUNATE for the treatment of patients with locally advanced or metastatic renal cell carcinoma https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260521060509HCM&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 11:11 AM
$HCM Share Price: $12.87 Contract Selected: Nov 20, 2026 $12.5 Calls Buy Zone: $3.06 – $3.78 Target Zone: $5.48 – $6.70 Potential Upside: 69% ROI Time to Expiration: 191 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
briefingcom
briefingcom Apr. 29 at 12:43 PM
$HCM: HUTCHMED announces that the New Drug Application for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260429060701HCM&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
NorthStarStats
NorthStarStats Apr. 2 at 1:42 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $WAB Score 100, $NUVL Score 98, $OMER Score 98, $HCM Score 98, $ZLAB Score 98
0 · Reply
Quantumup
Quantumup Apr. 1 at 4:42 PM
Truist reiterated $NUVB Buy; $12 $DSNKY DSKYF $HCM BAYRY LLY RIGL Here's what Truist said in its note: https://x.com/Quantumup1/status/2039382081814286759?s=20
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 5 at 2:40 PM
$HCM Q2 '25 Earnings Results & Recap Hutchison China MediTech reported 2025 consolidated revenue of $548.5M and net income of $456.9M, a significant increase from $37.7M in 2024, primarily driven by a divestment gain.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 5 at 2:40 PM
$HCM Q2 '25 Earnings Results & Recap HUTCHMED reported consolidated revenue of $548.5M and net income attributable to the company of $456.9M for 2025, resulting in basic earnings per share of $0.53.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 4:31 AM
$HCM Current Stock Price: $15.00
0 · Reply